Compare Crispr Therapeutics AG (CRSP) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Teucrium Soybean Fund — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Teucrium Soybean Fund trades at $27.57 (market cap $43.52M). The key difference: Crispr Therapeutics AG is far larger — about 112.1× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Teucrium Soybean Fund for 23 Days on average.
| CRSP | SOYB | |
|---|---|---|
Market Cap | $4.88B | $43.52M |
Volume | 2,861,747 | 32,585 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $74.92 | $28.14 |
52-Week Low | $44.34 | $21.55 |
Typical Hold Time | 77 Days | 23 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
SOYB trades at $27.57, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights potential catalysts from U.S.-China trade talks and agricultural commodity trends. Key support and resistance are tightly clustered around $27 and $28, indicating a consolidation phase.
The outlook is cautiously optimistic due to positive technical momentum and geopolitical developments, but fundamental data is unavailable, limiting valuation clarity. Risks include trade negotiation outcomes and broader commodity market volatility, requiring careful monitoring of upcoming earnings and guidance for a complete investment picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
